Athersys, Inc. operates as a biotechnology enterprise specializing in the research and development of regenerative medicine. Its clinical initiatives are directed towards addressing a range of health issues, including neurological disorders, cardiovascular diseases, inflammatory and immune system conditions, and pulmonary ailments. The company's primary therapeutic asset is MultiStem, an allogeneic stem cell treatment, which is currently in Phase III clinical trials. MultiStem is being evaluated for its efficacy in treating neurological damage subsequent to an ischemic stroke, acute respiratory distress syndrome, trauma-related complications, and in providing support for hematopoietic stem cell transplants, among other applications. Furthermore, Athersys is advancing MultiStem for veterinary purposes, aiming to foster tissue regeneration and recovery in animals afflicted with severe, unmet medical needs. The firm maintains key partnerships, including a collaboration with Healios K.K. to develop and commercialize MultiStem for ischemic stroke, ARDS, ophthalmic conditions, and diseases affecting the liver, kidneys, pancreas, and intestines. It also partners with the University of Minnesota to further develop the MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and its headquarters are located in Cleveland, Ohio.